MDT welcomes significant good news! On December 4, its Hugo robot-assisted surgical system received FDA approval for urological surgery, becoming the first approved soft tissue surgical robot from Medtronic in the U.S. market, marking the company's formal entry into the world's largest robotic surgery arena! This breakthrough, combined with solid performance and technological reserves, injects strong upward momentum into MDT!
As a medical technology giant, MDT has solid strength: the Hugo robot has completed tens of thousands of surgeries in over 30 countries worldwide, with modular design and 3D visualization technology creating differentiated advantages, targeting the annual market demand of 230,000 urological surgeries in the U.S.; at the same time, the Infuse bone graft product is advancing FDA approval for new indications, and the technology pipeline continues to realize value.
The demand in the medical technology sector is rigid, combined with the industry dividends from the expanding AI-MDT treatment ecosystem, MDT enjoys both policy benefits and growth potential. Now open Binance and search for MDT-related trading pairs to seize the opportunity of leading rise! Do you think MDT can break through historical highs in the future? Let's discuss in the comments～$MDT
